-+ 0.00%
-+ 0.00%
-+ 0.00%
Gebel (688566.SH): Application for marketing of tergixetine hydrobromide as an API accepted
Share
Listen to the news

Zhitong Finance App News, Gibbel (688566.SH) issued an announcement. The company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration. The company's application for the marketing of the pharmaceutical ingredient tergixetine hydrobromide under development has been accepted.

According to reports, the new antidepressant tergixetine hydrobromide is a new type of antidepressant drug with a novel multi-receptor mechanism being developed by the company, and has obvious antidepressant effects. Preliminary studies have shown that tejexetine hydrobromide can significantly prolong the half-life of the drug in the human body, increase the drug's blood concentration and AUC (a parameter that evaluates the degree of absorption of the drug in the body), slow the metabolic rate of the drug in the body, have good safety and tolerability, and is expected to become a novel antidepressant.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending